Press "Enter" to skip to content

ICMR Says Animal Blood Serum Containing Antibodies Can Control Severity of Covid-19

Image for illustration.

Antisera are blood serum derived from animals which include antibodies in opposition to particular antigens. They are injected to deal with or defend in opposition to particular ailments. After plasma remedy, it’s the newest remedy for use to deal with and forestall the severity of Covid-19 illness among the many sufferers.

  • IANS
  • Last Updated: October 1, 2020, 8:00 PM IST

  • FOLLOW US ON:

The Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based prescribed drugs and biologics firm have launched a well-established therapy modality to manage the severity of Covid-19 illness, the apex analysis institute knowledgeable on Thursday.

“The ICMR along with Biological E. Limited have developed “extremely purified antisera (raised in animals) for prophylaxis and therapy of the viral illness,” it stated.






Antisera are blood serum derived from animals which include antibodies in opposition to particular antigens. They are injected to deal with or defend in opposition to particular ailments. After plasma remedy, it’s the newest remedy for use to deal with and forestall the severity of Covid-19 illness among the many sufferers.

While plasma remedy couldn’t derive a passable end in decreasing mortality of the extreme sufferers of Covid-19, the ICMR has excessive hopes using on the antisera remedy. “Although, plasma recovered from patients experiencing Covid-19 could serve a similar purpose, the profile of antibodies, their efficacy and concentration keep varying from one patient to another and therefore make it an unreliable clinical tool for patient management,” the ICMR said.

However, the therapeutic use of antisera will not be new to medical science. The ICMR stated that it has been used to manage many viral and bacterial infections. Besides, the World Health Organisation (WHO) has listed it as a life-saving medication.

“Such measures have previously been used in medical science to control many viral and bacterial infections such as Rabies, Hepatitis B, Vaccinia virus, Tetanus, Botulism and Diphtheria,” the ICMR said.

While the usage of convalescent plasma as a therapy modality for Covid-19 has acquired authorisation for off-label use in India, a research performed by the ICMR prompt that its administration didn’t cut back mortality or development to extreme Covid-19 situation among the many sufferers.

The research, revealed on September 8, was performed in 39 tertiary care hospitals throughout the nation.

A complete of 464 contributors had been enrolled between April 22 and July 14 within the trial which was aimed to analyze its effectiveness for therapy of Covid-19.

However, the ICMR didn’t share particulars associated to scientific testing and trials of the antisera remedy on people.


Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    %d bloggers like this: